SISVEL
7.1.2016 17:46:21 CET | Business Wire | Press release
Sisvel, a global licensing company that has been dedicated to patent licensing since its foundation in 1982, has announced today that it is going beyond traditional patent licensing in how it acquires and monetizes patent portfolios and partners with IP players.
Sisvel is now offering its IP commercialization platform to anyone who wishes to gain greater value from Intellectual Property. This platform allows both IP Buyers and Sellers to use Sisvel’s proven network of partners, expertise in licensing and technical analysis – something no other entity now offers.
“IP buyers and sellers are in dire need to be directed by a competent player in the marketplace,” said Karel van Lelyveld, CEO of the Sisvel Group. “Sisvel has been active in this market for more than 30 years and we know what it takes to find the proverbial needle in a haystack. With our new IP Commercialization Platform we now provide easy and immediate access to buyers and sellers who want to transact assets. Our platform provides the simplicity and transparency needed to take back the market for those who develop innovative technologies and those who are seeking to get IP protection for innovative solutions”.
IP Commercialization Platform Features:
- Match for IP: Sisvel’s IP platform bridges buyer and seller requests and helps both parties achieve efficient solutions.
- Marketing IP Correctly: Sisvel’s team can help a company structure and optimize its Intellectual Property (IP) portfolio as well as identify the right assets to monetize.
- Finding the Proverbial Needle in a Haystack: Companies from around the world can now find specific IP assets in technical areas of interest, from selected sellers and pre-qualified portfolio opportunities.
“With Sisvel in the mix, there is no need to run around to ten or twenty different firms trying to buy access to the technologies you may need,” said Chuck Hausman, Vice President of Sisvel US.
Sisvel will formally unveil its new worldwide IP commercialization platform at CES 2016 with an announcement during a private reception on Thursday, January 7 from 4-6 p.m in the LVCC South Hall, Booth #1-20306. Sisvel’s management team will be available at the event to discuss the new platform’s benefits.
RSVP and further information:
Veronica Pugi veronica.pugi@sisvel.com
Sue
Ellen Schaming sschaming@hoogcomm.com
About Sisvel
Started in 1982 when Sisvel S.p.A. was founded
in Italy, the Sisvel Group has become a world leader in managing
intellectual property and maximizing the value of patent rights. The
Sisvel Group is global in scope and reach, with subsidiaries in Italy
(Sisvel and Sisvel Technology in None Torinese), the United States
(Sisvel US and Audio MPEG in Metropolitan Washington, DC), China (Sisvel
Hong Kong), Japan (Sisvel Japan in Tokyo), Germany (Sisvel Germany in
Stuttgart), Luxembourg (Sisvel International), and the United Kingdom
(Sisvel UK), with over one hundred professionals worldwide with
engineers, legal, and licensing expertise. Sisvel has a long history of
managing successful patent portfolios including those related to the
audio compression standards known as MP3 and MPEG Audio, and widespread
technologies such as OSD (On Screen Display), ATSS (Automatic Tuning &
Sorting System), and WSS (Wide Screen Signalling - for automatic
switching of television image formats). Sisvel currently operates patent
pools and joint licensing programs for the DVB-T, DVB-T2, LTE/LTE-A and
Wi-Fi standards, together with its Sisvel Wireless licensing program and
is in the process of creating a new licensing program for DVB-C2.
For additional information, please visit: www.sisvel.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160107005959/en/
Contact:
Media Contact
Sisvel Group
Veronica Pugi, Tel: +
39 011 990 4114
Senior Communications Officer
veronica.pugi@sisvel.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom